Sionna Therapeutics, Inc. (SION) is held by 6 of 149 tracked super-investor funds (144 filed in Q2) in 2026 Q2 13F filings, with 1 fund adding and 3 funds trimming or exiting versus the previous quarter. Insiders were net sellers over the last 90 days ($0 bought vs $21.8M sold). Latest close $2.97 as of Nov 18, 2026.
Data as of Nov 18, 2026 (prices) · 2026 Q2 13F filings (quarter ended Jun 30, 2026) · Latest Form 4: Sep 17, 2026 · Congress to Nov 16, 2026.
RA Capital Management · OrbiMed Advisors · Perceptive Advisors — 6 tracked funds hold SION. See all holders.
Insiders bought on the open market (0 purchases, $0) vs 2 sales ($21.8M). Insider trading
AVALYN PHARMA INC (AVLN) · BRIGHT MINDS BIOSCIENCES INC (DRUG) · MINERALYS THERAPEUTICS INC (MLYS) · MONOPAR THERAPEUTICS INC (MNPR) · PALISADE BIO INC (PALI) — stocks the same funds also hold. See all related stocks.
| Fund | Portfolio weight | Shares | Change vs prev. quarter |
|---|---|---|---|
| RA Capital Management | 3.79% | 9,905,045 | HELD Q3 filed Nov 16 |
| OrbiMed Advisors | 2.08% | 2,555,877 | TRIMMED (-27.6%) Q3 filed Nov 16 |
| Perceptive Advisors | 0.60% | 905,000 | ADDED (+37.4%) Q3 filed Nov 16 |
| Viking Global Investors | 0.40% | 3,195,181 | HELD Q3 filed Nov 16 |
| Deerfield Management | 0.31% | 680,916 | TRIMMED (-29.8%) Q3 filed Nov 16 |
| Baker Bros. Advisors | 0.09% | 400,000 | HELD Q3 filed Nov 16 |
| Polen Capital Management | — | — | EXITED |
Source: SEC Form 13F filings, quarter ended Jun 30, 2026. Change labels compare each fund’s 2026 Q2 filing with its previous filing. Fund counts aggregate every share class mapped to this ticker.
Price change since quarter-end: -92.6% from the close on the first trading day after the quarter ended (Jul 1, 2026) to the latest close (Nov 17, 2026). 13F does not report purchase prices — this is the price change since the quarter-end close, not a gain on any fund’s actual purchase.
Filing season: the Q3 2026 13F tracker follows every tracked fund’s filing for the quarter ended Sep 30, 2026, with its biggest buys and sells.
Closing prices (unadjusted for dividends), last 2 years — 448 trading days to Nov 18, 2026. Dashed lines mark 13F filing deadlines. Source: Yahoo Finance daily bars.
| Institutions holding | 151 of 8,857 filers |
| Long-only filers among them | 147 |
| Change vs 2026 Q1 | +34 net · 149 entered · 115 exited |
| Shares reported, all filers | 48,084,318 |
| Reported value, all filers | $2.1B |
Source: SEC Form 13F data sets — every filer's latest report for the quarter ended Jun 30, 2026, not just the tracked funds above; changes compare with the quarter ended Mar 31, 2026. Share counts and values are summed as reported in the filings (a small number of filers report values in thousands of dollars, so value totals are as-filed sums).
| Exchange | Nasdaq |
| Industry | Pharmaceutical Preparations (SIC 2834) |
| Net income · FY2025 | $-75.3M |
| Total assets · FY2025 | $326.0M |
| Shares outstanding | 45,212,399 |
| Market cap (at latest close) | $134.3M |
Source: SEC EDGAR company filings (submissions and company facts), collected Oct 30, 2026. Shares outstanding as reported Jul 31, 2026.
| Shares short · Oct 15, 2026 | 3,676,508 |
| Share of shares outstanding | 8.13% |
| Days to cover | 3.74 |
Shares short at recent settlements — Jul 31, 2026: 4.2M · Aug 14, 2026: 4.2M · Aug 31, 2026: 4.3M · Sep 15, 2026: 4.0M · Sep 30, 2026: 3.8M · Oct 15, 2026: 3.7M.
Source: FINRA Equity Short Interest (biweekly settlement data). Shares outstanding from SEC filings as of Jul 31, 2026.
| Shares failed to deliver · Oct 14, 2026 | 0 |
| Share of shares outstanding | 0.00% |
| Fails as a share of short interest · Oct 15, 2026 | 0.0% |
Fails to deliver at recent settlements — Jul 31, 2026: 0 · Aug 14, 2026: 14K · Aug 31, 2026: 41K · Sep 15, 2026: 338 · Sep 30, 2026: 0 · Oct 14, 2026: 0.
Source: SEC Fails-to-Deliver data (semi-monthly files, published about two weeks after each settlement date). Each figure is the balance of shares not yet delivered on that date; a stock absent from that date’s file counts as zero. See our research on whether fails to deliver predict returns. Shares outstanding from SEC filings as of Jul 31, 2026.
0 insiders bought on the open market in the last 90 days (0 purchases, $0), against 2 sales by 1 insider ($21.8M).
Source: SEC Form 4 filings. Open-market transactions only.
Recent open-market trades
| Date | Insider | Role | Buy / Sell | Shares | Price | Value | Source |
|---|---|---|---|---|---|---|---|
| Sep 17, 2026 | RA CAPITAL MANAGEMENT, L.P. | Sell | 3,415,011 | $6.32 | $21.6M | SEC filing | |
| Sep 17, 2026 | RA CAPITAL MANAGEMENT, L.P. | Sell | 33,800 | $7.46 | $252.1K | SEC filing |
Most recent open-market transactions in the same 90-day window, most recent first. Source: SEC Form 4 filings.
| Filed | Seller | Role | Shares to sell | Market value | Approx. sale date | Source |
|---|---|---|---|---|---|---|
| Sep 17, 2026 | RA Capital Healthcare Fund, L.P. | Director, 10% Stockholder | 3,448,811 | $21.8M | Sep 17, 2026 | SEC filing |
| Jul 6, 2026 | JENNIFER FITZPATRICK | Officer | 10,250 | $450.9K | Jul 6, 2026 | SEC filing |
| Jun 1, 2026 | OrbiMed Private Investments VIII, LP | Shareholder | 210,876 | $9.0M | May 29, 2026 | SEC filing |
| May 29, 2026 | OrbiMed Private Investments VIII, LP | Shareholder | 1,082,480 | $46.3M | May 29, 2026 | SEC filing |
| Mar 5, 2026 | JENNIFER FITZPATRICK | Officer | 10,250 | $354.3K | Mar 5, 2026 | SEC filing |
| Jan 22, 2026 | Rise Fund Sling, L.P. | Stockholder | 195,667 | $8.2M | Jan 22, 2026 | SEC filing |
| Jan 22, 2026 | Rise Fund Sling II, L.P. | Stockholder | 54,333 | $2.3M | Jan 22, 2026 | SEC filing |
| Dec 5, 2025 | JENNIFER R FITZPATRICK | Officer | 10,250 | $419.0K | Dec 5, 2025 | SEC filing |
| Nov 24, 2025 | OrbiMed Private Investments VIII, LP | Shareholder | 1,047,770 | $46.5M | Nov 24, 2025 | SEC filing |
| Nov 21, 2025 | RA Capital Healthcare Fund LP | Director, 10% Stockholder | 1,210 | $52.8K | Nov 21, 2025 | SEC filing |
A Form 144 notice is a planned sale, not a completed sale. Most recent first. Source: SEC Form 144 filings, 63,013 notices from Apr 13, 2023 to Oct 9, 2026.
| Filed | Form | Price change since disclosure |
|---|---|---|
| Sep 21, 2026 | SCHEDULE 13D/A | -49.0% (close Sep 22, 2026 → Nov 17, 2026) |
Reference close is the first trading day after the filing (Sep 22, 2026). A Schedule 13D reports beneficial ownership, not a purchase — there is no transaction price to show. Source: SEC EDGAR Schedule 13D filings.
| Filed | Filer | Form | Shares | % owned | Event date | Source |
|---|---|---|---|---|---|---|
| Sep 21, 2026 | RA Capital Management, L.P. | SC 13D/A | 6,476,193 | 14.3% | Sep 17, 2026 | SEC filing |
| May 15, 2026 | VIKING GLOBAL INVESTORS LP | SC 13G/A | 3,195,181 | 7.1% | Mar 31, 2026 | SEC filing |
| May 12, 2026 | Qatar Investment Authority | SC 13G/A | 2,020,258 | 4.5% | Mar 31, 2026 | SEC filing |
| Apr 20, 2026 | ORBIMED ADVISORS LLC | SC 13D/A | 2,967,722 | 6.6% | Apr 15, 2026 | SEC filing |
| Nov 7, 2025 | RA Capital Management, L.P. | SC 13D/A | 10,071,712 | 22.6% | Nov 5, 2025 | SEC filing |
| Oct 31, 2025 | SC 13G/A | — | — | — | SEC filing | |
| Oct 20, 2025 | Atlas Venture Fund XI, L.P. | SC 13D/A | 2,382,495 | 5.4% | Oct 16, 2025 | SEC filing |
| Jul 30, 2025 | JPMORGAN CHASE & CO. | SC 13G | 2,221,188 | 5.0% | Jun 30, 2025 | SEC filing |
| Jun 16, 2025 | Qatar Investment Authority | SC 13G | 2,209,775 | 5.0% | Jun 11, 2025 | SEC filing |
| Feb 18, 2025 | TPG GP A, LLC | SC 13D | 6,684,962 | 15.2% | Feb 10, 2025 | SEC filing |
One filing is one row; a filing may list several reporters and the first is shown. Figures are as filed, including amendments that report zero shares after a transfer. Source: SEC Schedule 13D/G filings, 57,443 filings parsed to Oct 2, 2026.
Data unavailable — no congressional STOCK Act transactions for this ticker were parsed in the current window (as of Nov 16, 2026).
Industry: Pharmaceutical Preparations (SIC 2834). Standing committees with jurisdiction over this industry: Senate Committee on Health, Education, Labor, and Pensions, House Committee on Energy and Commerce.
None of the members who traded this stock in the current window sit on these committees.
Assignments are the current (119th Congress) rosters. A trade made in an earlier Congress may have been made under a different assignment. Jurisdiction is by industry (SEC SIC code), not by anything the company said or did. Same rule as our committee-jurisdiction study.
Financial Screens
· Net-Net (NCAV) — Market cap below net current asset value
Red Flags
· Excess Accruals (Sloan) — Sloan accruals ratio beyond ±25%
Key figures
· Net-Net (NCAV) — NCAV: $222.3M · Market cap: $159.8M · NCAV / market cap: 1.39
· Excess Accruals (Sloan) — Accruals ratio: 33.7% · Net income: $-75.3M · Operating cash flow: $-66.3M · Investing cash flow: $-118.7M
Financial screens are computed from SEC company financial statements; red-flag models are screens, not verdicts — see Methodology.
· Insider BEST — appeared in 1 of the last 20 quarterly lists; latest 2025 Q1, ranked #8 of 50.
Also held by the tracked funds that hold SION — ranked by lift, the co-holding pattern described in Methodology: AVALYN PHARMA INC (AVLN) · BRIGHT MINDS BIOSCIENCES INC (DRUG) · MINERALYS THERAPEUTICS INC (MLYS) · MONOPAR THERAPEUTICS INC (MNPR) · PALISADE BIO INC (PALI) · PARABILIS MEDICINES INC (PBLS) · Pharvaris N.V. (PHVS) · RAPPORT THERAPEUTICS INC (RAPP).
| Filed | Items | Source |
|---|---|---|
| Nov 10, 2026 | 2.02 Results of Operations and Financial Condition · 9.01 Financial Statements and Exhibits | SEC filing |
| Sep 14, 2026 | 2.05 Costs Associated with Exit or Disposal Activities · 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers · 8.01 Other Events · 9.01 Financial Statements and Exhibits | SEC filing |
| Aug 10, 2026 | 8.01 Other Events · 9.01 Financial Statements and Exhibits | SEC filing |
Source: SEC EDGAR Form 8-K filings, latest first. Amendments (Form 8-K/A) are labeled as such. Item labels are the SEC's item titles; a filing can carry several items. Item 5.02 covers both departures and appointments, which this index does not distinguish.
AVALYN PHARMA INC (AVLN) · Track Record: how the signals scored · Practice timing on SION
One email a week: the week’s new filings and research. Subscribe free
Open the interactive tool →Live screens, charts and backtests for every tracked stock, fund and signal — free, no sign-up.